Working… Menu

Safety Study of FP-1039 To Treat Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00687505
Recruitment Status : Completed
First Posted : May 30, 2008
Last Update Posted : March 6, 2013
Information provided by (Responsible Party):
Five Prime Therapeutics, Inc.

Brief Summary:
The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.

Condition or disease Intervention/treatment Phase
Advanced Cancer Drug: FP-1039 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of FP-1039 in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors
Study Start Date : July 2008
Actual Primary Completion Date : May 2011
Actual Study Completion Date : June 2011

Arm Intervention/treatment
Experimental: 1
Single ascending doses
Drug: FP-1039
Intravenous weekly administration

Primary Outcome Measures :
  1. Safety and tolerability [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with metastatic or locally advanced unresectable solid tumors for which standard curative or supportive measures do not exist or are no longer effective
  • Male or female 18 years of age or older

Exclusion Criteria:

  • Presence or history of melanoma
  • Primary brain tumor
  • Presence or history of glaucoma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00687505

Layout table for location information
United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Texas
START (South Texas Accelerated Research Therapeutics)
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Five Prime Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Five Prime Therapeutics, Inc. Identifier: NCT00687505    
Other Study ID Numbers: FP1039-001
First Posted: May 30, 2008    Key Record Dates
Last Update Posted: March 6, 2013
Last Verified: March 2013